Compartir
Información de la revista
Contenido especial sobre el coronavirus SARS-CoV-2 (COVID-19) en Vacunas
COVID-19 immune response in adults post Measles-Rubella vaccination
Suwoyo Suwoyo, Erna Rahma Yani, Koekoeh Hardjito
10.1016/j.vacun.2023.05.004
Vacunas. 2023;24:341-7
Vacunación frente al SARS-CoV-2 en otoño de 2023: ¿a quién y cómo hay que vacunar?
Fernando Moraga-Llop, Campins-Marti
10.1016/j.vacun.2023.08.001
Vacunas. 2023;24:261-5
Immuno-informatics design of a multimeric epitope peptide-based vaccine against dengue virus serotype-2
Mohamed Sheik Tharik Abdul Azeeze, Rajaguru Arivuselvam
10.1016/j.vacun.2023.04.001
Vacunas. 2023;24:380-93
Autoimmune diseases related to post-SARS-CoV-2 vaccination: A rheumatology perspective
Farhad Dadgar, Jorge Casseb, Masoud Keikha
10.1016/j.vacun.2023.06.001
Vacunas. 2023;24:400-1
To assess mortality from COVID-19 in patients with comorbidities, it is crucial to perform an autopsy
Josef Finsterer
10.1016/j.vacun.2023.06.009
Vacunas. 2023;24:404-5
Factores asociados a la intención de vacunación contra el COVID-19 en Popayán, Cauca, Colombia
Omar Andrés Ramos Valencia, Yuliana Buitrón Gonzalez, Jorge Sotelo Sotelo Daza, Andrés Felipe Villaquiran
10.1016/j.vacun.2023.01.003
Vacunas. 2023;24:174-81
Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave
Younes Jesmani, Arezoo Bozorgomid, Fatemeh Khosravi Shadmani, Ali Dehbani, Babak Sayad
10.1016/j.vacun.2023.01.005
Vacunas. 2023;24:182-9
An immunoinformatics approach to study the epitopes of SARS-CoV-2 helicase, Nsp13
Sushant Kumar, Khushboo Kumari, Gajendra Kumar Azad
10.1016/j.vacun.2023.02.001
Vacunas. 2023;24:190-202
Impacto de la vacunación contra SARS-CoV-2 en la incidencia de infección en ámbito escolar
María Teresa Herrero-Diez, María Inés Salado-Valdivieso, Sara Carbajal-Domínguez, Marta Allué-Tango, Juan Carlos Villa-Caballero, Clara Berbel-Hernández
10.1016/j.vacun.2023.02.003
Vacunas. 2023;24:203-9
Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece
Petros Galanis, Aglaia Katsiroumpa, Irene Vraka, Vanessa Chrysagi, Olga Siskou, Olympia Konstantakopoulou, Theodoros Katsoulas, Parisis Gallos, Daphne Kaitelidou
10.1016/j.vacun.2023.05.005
Vacunas. 2023;24:210-7